Delivery Order SPE2DB24D2216-SPE2DB25FGPUK
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Envarsus XR 1 mg tablets (100-count) with a ceiling value of $1,288.86. This non-set-aside, competitively awarded contract is structured as a firm fixed price delivery order with an ultimate completion date of September 22, 2025. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Envarsus XR 1 mg tablets (100 count) with a ceiling value of $3,430.43. This firm fixed-price delivery order, with an ultimate completion date of August 25, 2025, represents a non-set-aside, competitively awarded contract. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Envarsus XR 0.75 mg tablets (30-count) with a ceiling value of $2,339.52. This delivery order represents a competitive, firm fixed-price procurement with no set-aside designation and is scheduled for ultimate completion by September 17, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Envarsus XR 1 mg tablets (100-count units) with a ceiling value of $1,718.48. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The pharmaceutical product will be performed and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Envarsus XR 1 mg tablets in quantities of 100 tablets, with a contract ceiling value of $1,718.48. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is scheduled for completion by September 8, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Envarsus XR 1 mg tablets in quantities of 100 units, with a contract ceiling value of $1,718.48. This firm fixed-price delivery order, with an ultimate completion date of October 1, 2025, represents a non-set-aside competitive award to support federal medical procurement requirements. The award is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units) under a firm fixed-price contract valued at $4,712.76, with completion targeted for September 10, 2025. This non-set-aside award represents a competitive procurement of pharmaceutical products to support federal healthcare needs. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical supplier within the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Envarsus XR 1 mg tablets (100-count units) with a ceiling value of $1,151.68. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 16, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. As a non-set-aside contract, this award reflects AmerisourceBergen's capability to compete...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Envarsus XR 1 mg tablets (100-count units) with a contract ceiling value of $2,148.10. This is a firm fixed-price delivery order with an ultimate completion date of September 29, 2025, and represents a non-competitive set-aside award. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Envarsus XR 1 mg tablets (100-count units) with a ceiling value of $1,288.86. This competitively awarded, firm fixed-price delivery order is set to be completed by September 8, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a single delivery order issued under a larger contract vehicle rather than a standalone...
- SPE2DB24D2216Indefinite Delivery Contract
- SPE2DB24D2216-SPE2DB25FGPUKDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Envarsus XR 1 mg tablets in a 30-count package, with a ceiling value of $1,553.40 and a firm fixed price structure. This is a non-set-aside competitive award with an ultimate completion date of October 6, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical prime vendor agreement valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency. The company's substantial prime IDC vehicle enables it to supply a broad range of pharmaceutical products, medical devices, and specialized healthcare commodities across multiple therapeutic domains to support defense health operations globally. The Envarsus XR tablets being delivered under this order represent a continuation of the company's role in supplying essential medications to federal healthcare programs through the DLA's pharmaceutical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 9/15/25 |